

Knobbe Martens Olson & Bear LLP**Intellectual Property Law**

550 West C Street
Suite 1200
San Diego CA 92101
Tel 619-235-8550
Fax 619-235-0178
kmob.com

May 19, 2004
5:20 PM

ORIGINAL WILL FOLLOW VIA:

- ☐ Mail
- ☐ Courier
- ☐ International Airmail
- ☐ Hand Delivery
- ☒ Will Not Follow
- ☐ With Enclosures
- ☐ Without Enclosures

Facsimile Transmittal Sheet**Confidentiality Notice:**

The documents accompanying this facsimile transmission contain confidential information which may be legally privileged. The information is intended only for the use of the recipient named below. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us; any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited.

TO: Examiner Maria B. Marvich, Ph.D.

FIRM: U.S. Patent and Trademark Office

FACSIMILE NO.: 703-872-9306

FROM: Erik T. Anderson

CLIENT CODE: UC081.001A

PAGES: 5 (INCLUDING THIS SHEET)

IF YOU DID NOT RECEIVE ALL OF THE PAGES, PLEASE CALL BACK IMMEDIATELY.

MESSAGE:

I attach possible claim amendments for discussion purposes only. We look forward to the Telephonic Interview scheduled for 1:00 p.m. (EST) on 5/20/04.

Don W. Martens
James B. Bear
Darrell L. Olson
William B. Bunker
William H. Nieman
Arthur S. Rose
James F. Loganek
Ned A. Israelson
Drew S. Hamilton
Jerry T. Sewell
John B. Spang, Jr.
Edward A. Schialter
Gerard von Hoffmann
Joseph R. Re
Catherine J. Holland
John M. Carson
Karen Vogel Well
Andrew H. Simpson
Jeffrey L. Van Hooser
Daniel E. Allman
Stephen C. Jensen
Vito A. Conuso III
William H. Shreve
Lynda J. Zadra-Symest
Steven J. Malepashy
Paul A. Stewart
Joseph F. Jennings
Craig G. Summers
AnneMarie Kaiser
Bronson R. Babcock
Thomas F. Smegal, Jr.
Michael H. Tronholm
Diane M. Reed
Ronald J. Schoenbaum
John R. King
Frederick S. Berrella
Nancy W. Vensko
John P. Glezentanner
Adeel S. Akhtar
Thomas R. Arno
David N. Weiss
Daniel Hart, Ph.D.
Douglas G. Muehlhauser
Lori Lee Yamato
Michael K. Friedland
Dale C. Hunt, Ph.D.
Richard E. Campbell
Stacey R. Halpern
Lee W. Henderson, Ph.D.
Mark M. Abumori

Jon W. Gurke
John W. Holcomb
Joseph M. Refaman, Ph.D.
Michael L. Fuller
Eric M. Nelson
Mark R. Benedict, Ph.D.
Paul N. Conover
Robert J. Roby
Sabing H. Lee
Karoline A. DeRaney
Joseph S. Cianfrani
William R. Zimmerman
Paul C. Steinhardt
Eric S. Furman, Ph.D.
Susan M. Noland
James W. Hill, M.D.
Deborah G. Shepherd
Glen L. Nuttall
Tizah Abd Lowe
Sanjivpal S. Gill
Rose M. Tlaxian, Ph.D.
Michael A. Gulliana
Mark J. Kertz
Rabinder N. Narula
Bruce S. Itchkawitz, Ph.D.
Michael S. Okamoto
John M. Grover
Mallory K. De Meritor
Irfan A. Lateef
Amy C. Christensen
Sharon S. Ng
Mark J. Gallagher, Ph.D.
David G. Jankowski, Ph.D.
Brian C. Horne
Payson J. LeMaitre
Sheila N. Swacop
Ben A. Katzensilenbogen
Linda H. Liu
Andrew N. Merickel, Ph.D.
David L. Hauser
James F. Markenhoff
Scott Loras Murray
Andrew M. Douglas
Marc T. Morley
Salima A. Merani, Ph.D.
Sam K. Tahmassebi, Ph.D.
Christy O. Lee
Jonathan A. Hyman
Curtiss C. Dostler
Joseph J. Mallon, Ph.D.

Thomas P. Krzeminski
Sean M. Murray
Eleanor Niu
Valerie L. Bracken
J. David Evered
Perry D. Oldham
Jerry L. Helmer, Ph.D.
Russell M. Jeld
Abraham W. Chuang
Pui Tong Ho, Ph.D.
Erik T. Anderson
John L. Paik
Jesse A. Rothwell
Marc C. Baumgartner
Danielle Kleener
Kyle F. Schuster
Raphael A. Gutierrez
Damian K. Jackson
Nathan A. Engels
Gregory A. Hermanson
Zi Y. Wong
John N. Randara
Matthew S. Baillinger
Davis K. Wiggins
Darryl H. Stegma, Ph.D.
Lauren J. Keller
Ted M. Cannon
Carol M. Pitzel
José A. Villalta
Shella R. Gibson
Andrew I. Kimmel
Curds R. Hufmire
Tina Chen
Brandon Gingrich, Ph.D.
Christopher L. Ross
Don W. Anthony, Ph.D.
John G. Rickenbroda
Aaron D. Barker
Christian A. Fox
M. Todd Heles
Ell A. Loois, Ph.D.
Jennifer L. Enmon, Ph.D.
Shusha A. Adque
Ryan E. Melnick, Ph.D.
Brian C. Laubitz
Yanna S. Bourla
Phillip M. Nelson
Karl L. Klassen
Jason T. Z...

Of Counsel
Louis J. Knobbe
Jerry R. Sailer
Japanese Patent Atty
Katsuhiko Aral
Tomohisa Sugiyama

Korean Patent Atty
Mincheol Kim
Haungsoo Choi

Scientists & Engineers
(Non-Lawyers)

Raimond J. Salenleke**
Khuram Rehman, Ph.D.
Jennifer Haynes, Ph.D.
Chao S. Chersakh, Ph.D.
James W. Ausley**
Kirk E. Pastorian, Ph.D.
Connie C. Tong, Ph.D.
Susanne Jepson, Ph.D.
Mira M. Brand**
Tiffany C. Miller**
James W. Chang, Ph.D.
Marina L. Gorday, Ph.D.
W. Frank Dauerer
Lang J. McHardy**
Karen J. Lenker
Chris Westberg, Ph.D.
Eric B. Ives, Ph.D.
Raymond D. Smith, Ph.D.

* A Professional Corporation
† Also Barholder ALAW (Eng & Mech)
** U.S. Patent Agent
†† Also Solicitor (Eng & Mech)

RECEIVED
CENTRAL FAX CENTER

MAY 19 2004

Unofficial

2040 Main Street
14th Floor
Irvine, CA 92614
Tel 949-760-0404

201 California Street
Suite 1150
San Francisco CA 94111
Tel 415-954-4114

1901 Avenue of the Stars
Suite 1500
Los Angeles CA 90087
Tel 310-551-3450

3403 Tenth Street
Suite 700
Riverside CA 92501
Tel 951-781-8231

1114 Marsh Street
San Luis Obispo CA 93401
Tel 805-547-5380
Fax 805-547-5380

To: Examiner Maria B. Marvich, Ph.D.

Possible Claim Amendments for discussion during Interview 5/20/04

U.S. Application No. 10/042,775

Attorney ref: UC081.001A

NOT FOR ENTRY INTO THE FILE

1. A method for recombinantly producing functional ataxia-telangiectasia (ATM) protein, comprising:

providing a viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter;

infecting ATM deficient mammalian L3 cells with said viral vector, wherein said mammalian L3 cells are thereby made to produce functional ATM protein; and

isolating said functional ATM protein produced by said mammalian L3 cells.

2. The method of Claim 1, wherein said viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter is a vaccinia viral vector.

3. ~~(cancelled) The method of Claim 1, wherein said viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter is a variola viral vector.~~

4. (cancelled)

5. The method of Claim 1, wherein said promoter is a synthetic early/late viral promoter.

6. ~~(cancelled) The method of Claim 1, wherein said mammalian cells are human cells.~~

7. ~~(cancelled) The method of Claim 1, wherein said ATM deficient mammalian cells are HeLa cells.~~

8. (cancelled)

9. ~~(cancelled) The method of Claim 1, wherein said ATM deficient mammalian cells are L3 cells.~~

10. The method of Claim 1, further wherein said ATM-deficient mammalian L3 cells producing said functional ATM protein exhibit regain of ATM function.

11. The method of Claim 1 wherein isolating said functional ATM protein comprises binding an anti-ATM antibody to said ATM protein.

12. The method of Claim 1, where said cDNA encoding the ATM protein is modified to comprise a FLAG epitope.

13. The method of Claim 12, wherein isolating said functional ATM protein comprises binding an antibody specific for the FLAG epitope to said ATM protein.

14. The method of Claim 1, wherein said functional ATM protein is produced at a level of greater than 2 μ g substantially purified ATM protein per 300 grams fresh weight of host cells or host tissue.

15. The method of Claim 1, further wherein said functional ATM protein is capable of phosphorylating ATM substrates.

16. The method of Claim 15, wherein said substrates comprise p53 and PHAS-1.

17. A method for recombinantly producing functional ataxia-telangiectasia (ATM) protein, comprising:

providing a vaccinia viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter;

infecting mammalian cells with said vaccinia viral vector, wherein said mammalian cells produce functional ATM protein; and

isolating said functional ATM protein produced by said mammalian cells by binding an anti-ATM antibody to the ATM protein;

wherein the yield of functional ATM protein is at least 2 μ g substantially purified ATM protein per 300 grams fresh weight of mammalian cells.

18. The method of Claim 17, wherein said the yield of functional ATM protein is greater than 5 μ g substantially purified ATM protein per 300 grams fresh weight of mammalian cells.

19. The method of Claim 17, wherein said mammalian cells are human cells.

20. (cancelled)

21. The method of Claim 17, where said cDNA encoding the ATM protein is modified to comprise a FLAG epitope.

22. (cancelled)

23. A method for recombinantly producing functional ataxia-telangiectasia (ATM) protein, comprising:

providing a vaccinia viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter;

infecting mammalian cells with said vaccinia viral vector, wherein said mammalian cells produce functional ATM protein; and

isolating said functional ATM protein produced by said mammalian cells wherein said functional ATM protein is produced at a level of greater than 2 µg substantially purified ATM protein per 300 grams fresh weight of host cells or host tissue.

24. The method of Claim 23, wherein said mammalian cells are human cells.

25. The method of Claim 23 wherein said mammalian cells are L3 cells.

26. The method of Claim 23, wherein said isolating said functional ATM protein comprises binding an anti-ATM antibody to the ATM protein.

27. The method of Claim 23, where said cDNA encoding the ATM protein is modified to comprise a FLAG epitope.

28. The method of Claim 23, wherein isolating said functional ATM protein comprises binding an antibody specific for the FLAG epitope to said ATM protein.

29. (new) A method for recombinantly producing functional ataxia-telangiectasia (ATM) protein, comprising:

providing a vaccinia viral vector comprising a cDNA encoding the ATM protein operably linked to a promoter;

infecting ATM deficient mammalian cells with said vaccinia viral vector, wherein said mammalian cells are thereby made to produce functional ATM protein; and

isolating said functional ATM protein produced by said mammalian cells.

30. (new) The method of Claim 29 wherein said promoter is a synthetic early/late viral promoter.

31. (new) The method of Claim 29 wherein said mammalian cells are human cells.

32. (new) The method of Claim 29 wherein said ATM deficient mammalian cells are L3 cells.

33. (new) The method of Claim 29, wherein said ATM-deficient mammalian cells producing said functional ATM protein exhibit regain of ATM function.

34. (new) The method of Claim 29 wherein isolating said functional ATM protein comprises binding an anti-ATM antibody to said ATM protein.

35. (new) The method of Claim 29, wherein said cDNA encoding the ATM protein is modified to comprise a FLAG epitope.

36. (new) The method of Claim 35, wherein isolating said functional ATM protein comprises binding an antibody specific for the FLAG epitope to said ATM protein.

37. (new) The method of Claim 29, further wherein said functional ATM protein is capable of phosphorylating ATM substrates.

38. (new) The method of Claim 37, wherein said substrates comprise p53 and PHAS-1.

S:\DOCS\ETA\ETA-2134.DOC
051904